CytomX Therapeutics, Inc.
CTMXNext catalyst
Data Readout - Varsetatug masetecan (Varseta-M, CX-2051)
Get an email about CTMX's next catalysts
Track CytomX Therapeutics (CTMX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
Data Readout - Varsetatug masetecan (Varseta-M, CX-2051)
For Metastatic colorectal cancer (relapsed/refractory); also gastric/GEJ cancer, EpCAM-selected PDAC and biliary tract cancer. CytomX reported Q3 2026 results and a business update, noting Varseta-M received FDA Fast Track designation for relapsed/refractory mCRC in August. A Phase 1 monotherapy mCRC data update is expected in January 2027, with a Phase 1/2 chemotherapy combination study in 2L mCRC planned to start by year-end 2026.
SourceMarket Overview
Stock performance and key metrics
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in CytomX Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in CytomX Therapeutics, Inc.'s (CTMX) pipeline across Phase 2. Its lead program is CX-072 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CytomX Therapeutics, Inc.'s next FDA catalyst?→
CytomX Therapeutics, Inc.'s (CTMX) next tracked catalyst is a data readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CTMX biotech catalysts?→
Add CTMX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CytomX Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.